Australian company Dimerix (ASX:DXB) has announced it has received firm commitments to raise $20 million via an institutional placement with proceeds to complete the ACTION3 Phase 3 clinical study in patients with debilitating kidney disease. …
Dimerix raises $20 million to continue and expand late-stage clinical trial of DMX-200
March 12, 2024 Australian Biotech
Latest Video
New Stories
-
A shorter name and bolder blue for Novo in global rebrand
September 15, 2026 - - Latest News -
Australia's 2026 flu vaccination season barely moves the needle on uptake
September 15, 2026 - - Latest News -
Persistent fatigue could be an overlooked sign of liver disease
September 15, 2026 - - Latest News -
Noxopharm moves lupus skin therapy toward next human trial
September 14, 2026 - - Australian Biotech -
Entropy's psychedelic infusion keeps binge eating disorder at bay three months after treatment ends
September 14, 2026 - - Latest News -
Diabetes and cancer blood tests reach WA and NT patients under new Healius deal
September 14, 2026 - - Australian Biotech -
FDA clears Telix's Pixclara as the world's first approved brain cancer imaging drug
September 14, 2026 - - Australian Biotech